Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 15

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 15
---
 exercise. The purchase agreement, or July Purchase Agreement,
contains customary representations, warranties and covenants of the Company and each Investor, and customary indemnification provisions
for a transaction of this type. Pursuant to the terms of the July Purchase Agreement, we agreed to be subject to a lock-up period on subsequent
equity sales, which has since expired. We also agreed to not issue any securities that are subject to a price reset based on the trading
prices of our Ordinary Shares or upon a specified or contingent event in the future or enter into any agreement to issue securities at
a future determined price for a period of 180 days following the closing date of the Offerings, subject to certain exceptions. Additionally,
we agreed to reduce the exercise price of our existing Series E warrants, Series G warrants and Series H warrants held by each Investor
to $25.00 per Depositary Share.

In
connection with the Offerings, we entered into a placement agency agreement, or the Placement Agent Agreement, with Ladenburg Thalmann
& Co. Inc., or Ladenburg, pursuant to which we engaged Ladenburg as the exclusive placement agent for the Offerings. We agreed to
pay Ladenburg a cash fee in an amount equal to 8.0% of the aggregate gross proceeds of the Offerings and to issue to Ladenburg or its
designees the July 2024 Placement Agent Warrants. We also agreed to pay Ladenburg a management fee equal to 1.0% of the gross proceeds
raised in the Offerings and an expense allowance of up to $85,000 for legal fees and other out-of-pocket expenses. The July 2024 Placement
Agent Warrant has substantially the same terms as the Series J Warrants, except that the exercise price of the July 2024 Placement Agent
Warrants is $31.25 and the term of the July 2024 Placement Agent Warrants will terminate on the three-year anniversary of the initial
exercise date.

Warrant Inducement

On
May 22, 2024, we entered into letter agreements, or the Warrant Agreements, with certain accredited investors, collectively referred to
as the Holders, that were holders of an aggregate of 62,906 of our outstanding Series E warrants exercisable for $55.00 per Depositary
Share, or Series E Warrants, and an aggregate of 61,275 of our outstanding Series F warrants exercisable for $55.00 per Depositary Share,
or Series F